S. Marsh

发表

Cytochrome P450 2C9-CYP2C9.

Derek J Van Booven, R. Altman, K. Sangkuhl, 2010, Pharmacogenetics and genomics.

DNA Repair Pathway Profiling and Microsatellite Instability in Colorectal Cancer

M. Watson, P. Goodfellow, H. McLeod, 2006, Clinical Cancer Research.

Fast and frugal trees: translating population-based pharmacogenomics to medication prioritization.

Tibor van Rooij, Todd Wareham, I. Rooij, 2015, Personalized medicine.

Personalized medicine policy challenges: measuring clinical utility at point of care

Donna M. Wilson, S. Marsh, T. van Rooij, 2012, Expert review of pharmacoeconomics & outcomes research.

Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.

Robert Brown, H. McLeod, S. Marsh, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin

M. Rieder, P. Ridker, R. Glynn, 2008, Clinical pharmacology and therapeutics.

Irinotecan pathway genotype analysis to predict pharmacokinetics.

Sharon Marsh, Ron H J Mathijssen, Mats O Karlsson, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Irinotecan Pathway Genotype Analysis to Predict Pharmacokinetics 1

H. McLeod, J. Verweij, S. Marsh, 2003 .

Improving oncology outcomes through targeted therapeutics will require electronic delivery systems.

S. Marsh, T. van Rooij, 2011, Future oncology.

ABCG2 Pharmacogenetics

H. McLeod, J. Verweij, S. Marsh, 2004, Clinical Cancer Research.

Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes

H. McLeod, S. Marsh, M. Egorin, 2006, Investigational New Drugs.

Variants in the SLCO1B3 Gene: Interethnic Distribution and Association with Paclitaxel Pharmacokinetics

H. McLeod, J. Verweij, S. Marsh, 2007, Clinical pharmacology and therapeutics.

ABCG2 Pharmacogenetics: Ethnic Differences in Allele Frequency and Assessment of Influence on Irinotecan Disposition

H. McLeod, J. Verweij, S. Marsh, 2004 .

CYP3A4 and CYP3A5 genotyping by Pyrosequencing

H. McLeod, S. Marsh, A. Garsa, 2005, BMC Medical Genetics.

Population variation in VKORC1 haplotype structure

C. Eby, S. Marsh, C. King, 2006, Journal of thrombosis and haemostasis : JTH.

Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy.

S. Marsh, Geoffrey Liu, 2009, Advanced drug delivery reviews.

A Bridging Opportunities Work-frame to develop mobile applications for clinical decision making

S. Marsh, T. van Rooij, Serena Rix, 2015, Future science OA.

Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.

D. Sargent, S. Thibodeau, H. McLeod, 2010, Journal of Clinical Oncology.

Irinotecan‐induced Diarrhea: Functional Significance of the Polymorphic ABCC2 Transporter Protein

J. Verweij, D. Kroetz, S. Marsh, 2007, Clinical pharmacology and therapeutics.

Pharmacogenetic Pathway Analysis of Docetaxel Elimination

A. Wolff, J. Verweij, S. Marsh, 2009, Clinical pharmacology and therapeutics.

Integrating genomic-based clinical decision support into electronic health records.

S. Marsh, T. van Rooij, Amr Al Mallah, 2010, Personalized medicine.

Natriuretic peptide receptor 3 genotype modulates the relationship between B-type natriuretic peptide and left ventricular end-diastolic pressure

M. Rich, H. McLeod, S. Marsh, 2006 .

Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer

Xia Li, W. Shannon, S. Marsh, 2007, The Pharmacogenomics Journal.

Concordance of pharmacogenetic markers in germline and colorectal tumor DNA.

P. Goodfellow, H. McLeod, S. Marsh, 2005, Pharmacogenomics.

Pharmacogenetics goes 3D

H. McLeod, S. Marsh, 2005, Nature Genetics.

Pharmacogenomic Markers for Cancer Therapy

S. Marsh, 2010, Molecular Diagnostics.

Research Highlights: Highlights from the latest articles in colorectal cancer pharmacogenomics

S. Marsh, 2012 .

Challenges of incorporating pharmacogenomics into clinical practice.

S. Marsh, T. van Rooij, 2009, Gastrointestinal cancer research : GCR.

Pharmacogenomics of Taxane/Platinum Therapy in Ovarian Cancer

S. Marsh, 2009, International Journal of Gynecologic Cancer.

Pyrosequencing of clinically relevant polymorphisms.

H. McLeod, S. Marsh, C. King, 2005, Methods in molecular biology.

Frequency of compound genotypes associated with beta-blocker efficacy in congestive heart failure.

J. Spertus, H. McLeod, S. Marsh, 2004, Pharmacogenomics.

Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients

H. McLeod, J. Verweij, S. Marsh, 2004, Investigational New Drugs.

Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer.

H. McLeod, S. Marsh, J. McKay, 2001, International journal of oncology.

Taxane pathway.

R. Altman, T. Klein, H. McLeod, 2009, Pharmacogenetics and genomics.

COMMENT ON “A FRAMESHIFT MUTATION AND ALTERNATE SPLICING IN HUMAN BRAIN GENERATE A FUNCTIONAL FORM OF THE PSEUDOGENE CYTOCHROME P4502D7 THAT DEMETHYLATES CODEINE TO MORPHINE”

H. McLeod, S. Marsh, J. Hoskins, 2005, Drug Metabolism and Disposition.

ABCB1 (MDR 1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy

K. Byth, Robert Brown, S. Fereday, 2008, Clinical Cancer Research.

Distribution of ITPA P32T alleles in multiple world populations

H. McLeod, S. Marsh, C. King, 2004, Journal of Human Genetics.

Characterization of the topoisomerase I locus in human colorectal cancer.

H. McLeod, S. Marsh, J. Cassidy, 2000, Cancer genetics and cytogenetics.

Novel thymidylate synthase enhancer region alleles in African populations

H. McLeod, S. Marsh, D. Ofori-Adjei, 2000, Human mutation.

pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil (5fu)/cpt-11, 5fu/oxaliplatin (oxal), or Cpt-11/oxal therapy for advanced colorectal cancer (crc): Results from an intergroup trial : 1013

D. Sargent, S. Thibodeau, H. McLeod, 2003 .

Pharmacogenomics of third-generation aromatase inhibitors

S. Marsh, A. Turkistani, 2012, Expert opinion on pharmacotherapy.

CYP3A5 Polymorphism and the Ethnic Differences in Cyclosporine Pharmacokinetics in Healthy Subjects 1

H. McLeod, S. Marsh, D. Min, 2004, Therapeutic drug monitoring.

ABCB1 2677G>T/A Genotype and Paclitaxel Pharmacogenetics in Ovarian Cancer

Robert Brown, H. McLeod, S. Marsh, 2006, Clinical Cancer Research.

Thymidylate synthase pharmacogenetics in colorectal cancer.

S. Marsh, H. Mcleod, H. L. McLeod, 2001, Clinical colorectal cancer.

Platinum pathway.

R. Altman, L. Gong, T. Klein, 2009, Pharmacogenetics and genomics.

UGT1A1*28, toxicity and outcome in advanced colorectal cancer: Results from Trial N9741.

D. Sargent, H. McLeod, R. Goldberg, 2006, Journal of Clinical Oncology.

Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis.

H. McLeod, S. Marsh, J. McKay, 2002, Oncology reports.

Doxorubicin pathways: pharmacodynamics and adverse effects

Tina Hernandez-Boussard, Connie Oshiro, Russ B Altman, 2011, Pharmacogenetics and genomics.

Gut Microbiota and Metagenomic Advancement in Digestive Disease

S. Marsh, Junbo Hu, Chaodong Wu, 2016, Gastroenterology research and practice.

Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis.

Sharon Marsh, Howard L McLeod, Robert Culverhouse, 2008, The Journal of rheumatology.

Thymidylate synthase pharmacogenetics

Sharon Marsh, S. Marsh, 2005, Investigational New Drugs.

The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background

Sharon Marsh, S. Marsh, Junbo Hu, 2016, Gastroenterology research and practice.

Pyrosequencing applications.

S. Marsh, 2007, Methods in molecular biology.

Pharmacogenomic assessment of carboxylesterases 1 and 2.

P. Kwok, M. Xiao, H. McLeod, 2004, Genomics.

Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.

G. Peters, H. McLeod, E. Bloemena, 2002, Biochimica et biophysica acta.

The Increasing Complexity of Mercaptopurine Pharmacogenomics

S. Marsh, D. V. van Booven, 2009, Clinical pharmacology and therapeutics.

SNP databases and pharmacogenetics: great start, but a long way to go

Sharon Marsh, Howard L McLeod, P. Kwok, 2002, Human mutation.

Colorectal cancer genomics: evidence for multiple genotypes which influence survival

H. McLeod, S. Marsh, N. Haites, 2001, British Journal of Cancer.

Recommendations for locus‐specific databases and their curation

M. Vihinen, J. Beckmann, A. Brookes, 2008 .

Ferredoxin reductase: pharmacogenomic assessment in colorectal cancer.

H. McLeod, S. Marsh, Jinsheng Yu, 2003, Cancer research.

Concordance Between Tumor and Germline DNA

S. Marsh, 2008 .

Germline Polymorphisms in EGFR and Survival in Patients With Lung Cancer Receiving Gefitinib

M. Hidalgo, S. Marsh, S. Baker, 2008, Clinical pharmacology and therapeutics.

The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer.

H. McLeod, J. Kolesar, S. Marsh, 2011, Oncology reports.

Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors.

S. Marsh, J. Cassidy, H. Mcleod, 2001, Cancer research.

Comparative genomic hybridization analysis of chromosomal alterations induced by the development of resistance to thymidylate synthase inhibitors.

P. Johnston, H. McLeod, S. Marsh, 1998, Cancer research.

Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: a systematic review.

H. Mackay, S. Marsh, Geoffrey Liu, 2012, Gynecologic oncology.

CpG island methylation of DNA damage response genes in advanced ovarian cancer.

Jacqueline A. Hall, Robert Brown, H. McLeod, 2005, Cancer research.

Discovery and validation of vascular endothelial growth factor (VEGF) pathway polymorphisms in esophageal adenocarcinoma outcome.

H. Mackay, A. Azad, S. Marsh, 2015, Carcinogenesis.

Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype

Sharon Marsh, Howard L McLeod, Alex Sparreboom, 2004, Clinical pharmacology and therapeutics.

PharmGKB summary: methotrexate pathway.

Russ B Altman, Sharon Marsh, Howard L McLeod, 2011, Pharmacogenetics and genomics.

Genotypes associated with myocardial infarction risk are more common in African Americans than in European Americans.

Sharon Marsh, Howard L McLeod, William D Shannon, 2004, Journal of the American College of Cardiology.

Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel

Sharon Marsh, Mats O Karlsson, Howard L McLeod, 2005, Clinical Cancer Research.

Pharmacogenetics and oncology treatment for breast cancer

H. McLeod, S. Marsh, 2007, Expert opinion on pharmacotherapy.

Irinotecan Pharmacogenetics: Influence of Pharmacodynamic Genes

Taylor J. Maxwell, Derek J Van Booven, H. McLeod, 2008, Clinical Cancer Research.

Irinotecan Pharmacogenetics : Influence of PharmacodynamicGenes

Taylor J. Maxwell, Derek J Van Booven, H. McLeod, 2008 .

Interethnic variability of ERCC2 polymorphisms

S. Marsh, R. Freimuth, J. Yu, 2005, The Pharmacogenomics Journal.

Pharmacogenomic assessment of Mexican and Peruvian populations.

Derek J Van Booven, H. McLeod, Derek J. Van Booven, 2015, Pharmacogenomics.

Colorectal cancer pharmacogenomics

S. Marsh, Jinsheng Yu, J. Hoskins, 2006 .

Irinotecan pharmacogenomics.

S. Marsh, J. Hoskins, 2010, Pharmacogenomics.

Pharmacogenetics of colorectal cancer

S. Marsh, 2005, Expert opinion on pharmacotherapy.

β2-Adrenergic Receptor Genotype and Survival AmongPatients Receiving β-Blocker Therapy After an Acute Coronary Syndrome

J. Spertus, H. McLeod, S. Marsh, 2005 .

Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome.

J. Spertus, H. McLeod, S. Marsh, 2005, JAMA.

Pharmacogenetically relevant polymorphisms in Portugal.

S. Marsh, A. Amorim, M. Prata, 2007, Pharmacogenomics.

Cancer pharmacogenetics

S. Marsh, H. Mcleod, H. McLeod, 2004, British Journal of Cancer.

ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients.

Bingshu E. Chen, L. Seymour, M. Tsao, 2016, Cancer epidemiology.

Global pharmacogenetics: giving the genome to the masses.

Sharon Marsh, Howard L McLeod, Derek J Van Booven, 2006, Pharmacogenomics.

Polymorphism discovery in 51 chemotherapy pathway genes.

Derek J Van Booven, P. Kwok, M. Xiao, 2005, Human molecular genetics.

Ethnic differences in pharmacogenetically relevant genes.

S. Marsh, H. Mcleod, R. Engen, 2006, Current drug targets.

Chapter 8 – Pyrosequencing

S. Marsh, 2010 .

Systems pharmacogenomics in yeast.

P. Cahan, H. McLeod, S. Marsh, 2006, Pharmacogenomics.

Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations.

H. McLeod, S. Marsh, T. Li, 1999, Genomics.

Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis.

H. McLeod, W. Shannon, R. Culverhouse, 2004, Pharmacogenomics.

DNA methylotype analysis in colorectal cancer.

M. Watson, H. McLeod, R. Culverhouse, 2008, Oncology reports.

Pharmacogenetics of irinotecan toxicity.

H. McLeod, S. Marsh, 2004, Pharmacogenomics.

Pharmacogenomics: from bedside to clinical practice.

H. McLeod, S. Marsh, 2006, Human molecular genetics.

eHealth: past and future perspectives.

Tibor van Rooij, S. Marsh, 2016, Personalized medicine.

Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway

H. McLeod, S. Marsh, D. Murry, 2004, The Pharmacogenomics Journal.

Pharmacogenetics: global clinical markers.

S. Marsh, 2008, Pharmacogenomics.

Pharmacogenetics in Cancer

S. Marsh, 2012 .

Genetic Variation in the B-Type Natiuretic Peptide Pathway Affects BNP Levels

M. Rich, H. McLeod, S. Marsh, 2007, Cardiovascular Drugs and Therapy.

Pyrosequencing of clinically relevant polymorphisms.

S. Marsh, C. King, Cristi R. King, 2013, Methods in molecular biology.

Application of pharmacogenomics in the individualization of chemotherapy for gastrointestinal malignancies.

H. McLeod, S. Marsh, C. King, 2004, Clinical colorectal cancer.

Pharmacogenetic analysis of clinically relevant genetic polymorphisms.

H. McLeod, S. Marsh, C. Rose, 2003, Methods in molecular medicine.

Single Nucleotide Polymorphisms and DNA Methylation Analysis Using Pyrosequencing Methods

S. Marsh, Jinsheng Yu, 2008 .

CEPH individuals are representative of the European American population: implications for pharmacogenetics.

J. Watters, H. McLeod, S. Marsh, 2005, Pharmacogenomics.

Identification of NR1I2 genetic variation using resequencing

P. Kwok, M. Xiao, Nicholas J. Addleman, 2007, European Journal of Clinical Pharmacology.

Impact of Pharmacogenomics on Clinical Practice in Oncology

S. Marsh, 2012, Molecular Diagnosis & Therapy.

Integrating pharmacogenomics into oncology clinical practice

S. Marsh, M. Phillips, 2008, Expert review of clinical pharmacology.

PharmGKB summary: fluoropyrimidine pathways.

Russ B Altman, Sharon Marsh, Howard L McLeod, 2010, Pharmacogenetics and genomics.

A Phase II Study of Irinotecan and Carboplatin in Advanced Non-small Cell Lung Cancer with Pharmacogenomic Analysis: Final Report

R. Govindan, H. McLeod, W. Read, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Validation of microRNA pathway polymorphisms in esophageal adenocarcinoma survival

H. Mackay, A. Azad, S. Marsh, 2017, Cancer medicine.

Influence of ethnicity on pharmacogenetic variation in the Ghanaian population

E. Peters, S. Marsh, D. Booven, 2009, The Pharmacogenomics Journal.

Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase.

H. McLeod, S. Marsh, R. Freimuth, 2003, Clinical chemistry.

Hoosier Oncology Group Randomized Phase II Study of Docetaxel, Vinorelbine, and Estramustine in Combination in Hormone-Refractory Prostate Cancer with Pharmacogenetic Survival Analysis

Cynthia S. Johnson, Lang Li, H. McLeod, 2006, Clinical Cancer Research.

2-Adrenergic Receptor Genotype and Survival Among Patients Receiving -Blocker Therapy After an Acute Coronary Syndrome

J. Spertus, H. McLeod, S. Marsh, 2005 .

Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies.

H. McLeod, S. Marsh, P. Fracasso, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.